Compound details
Officinalisin II
| Compound ID | CDAMM02355 |
|---|---|
| Common name | Officinalisin II | IUPAC name | 2-[4-[6-hydroxy-16-[4-hydroxy-6-(hydroxymethyl)-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-5-(3,4,5-trihydroxyoxan-2-yl)oxyoxan-2-yl]oxy-7,9,13-trimethyl-5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosan-6-yl]-2-methylbutoxy]-6-(hydroxymethyl)oxane-3,4,5-triol |
| Molecular formula | C50H84O23 |
| Retention time | 4.5 |
|---|---|
| Adduct | [M+Na]+ |
| Actual mz | 1075.53 | Theoretical mz | 1075.53 |
| Error | 0.2 |
| Ionizaton mode | Positive |
| Instrument type | LC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60 |
| Score | 5.9907 |
| Inchi key | TUDCHFPLNJLAIG-UHFFFAOYNA-N |
|---|---|
| Smiles | OCC1OC(OCC(C)CCC2(O)OC3CC4C5CCC6CC(OC7OC(CO)C(OC8OCC(O)C(O)C8O)C(O)C7OC9OC(CO)C(O)C(O)C9O)CCC6(C)C5CCC4(C)C3C2C)C(O)C(O)C1O |
| Superclass | Lipids and lipid-like molecules |
| Class | Steroids and steroid derivatives |
| Uniprot ID | Gene name | Target name | TTD_ID | Prediction source |
|---|---|---|---|---|
| P15692 | VEGFA | Vascular endothelial growth factor A | T20761 | SwissTargetPrediction |
| P05230 | FGF1 | Acidic fibroblast growth factor | T18639 | SwissTargetPrediction and SEA |
| P09038 | FGF2 | Basic fibroblast growth factor | T31621 | SwissTargetPrediction |
| Q9Y251 | HPSE | Heparanase | T47623 | SwissTargetPrediction |
| P60568 | IL2 | Interleukin-2 | T61698 | SEA |
| P17931 | LGALS3 | Galectin-3 | T72038 | SEA |
| P04746 | AMY2A | Pancreatic alpha-amylase | T86918 | SEA |
| P14679 | TYR | Tyrosinase | T97035 | SEA |
| O15439 | ABCC4 | Multidrug resistance protein 4 | T39919 | SEA |
| TTD_ID | Disease_ID | Disease name | ICD_11 | Uniprot ID | Gene names |
|---|---|---|---|---|---|
| T20761 | DI0095 | Colorectal cancer | [ICD-11: 2B91] | P15692 | VEGFA |
| T20761 | DI0365 | Retinopathy | [ICD-11: 9B71] | P15692 | VEGFA |
| T20761 | DI0430 | Vascular system developmental anomaly | [ICD-11: LA90] | P15692 | VEGFA |
| T18639 | DI0081 | Chronic arterial occlusive disease | [ICD-11: BD4Z] | P05230 | FGF1 |
| T18639 | DI0102 | Coronary atherosclerosis | [ICD-11: BA52] | P05230 | FGF1 |
| T31621 | DI0005 | Acne vulgaris | [ICD-11: ED80] | P09038 | FGF2 |
| T47623 | DI0020 | African trypanosomiasis | [ICD-11: 1F51] | Q9Y251 | HPSE |
| T47623 | DI0310 | Ocular disease | [ICD-11: N.A.] | Q9Y251 | HPSE |
| T61698 | DI0275 | Multiple sclerosis | [ICD-11: 8A40] | P60568 | IL2 |
| T61698 | DI0361 | Renal cell carcinoma | [ICD-11: 2C90] | P60568 | IL2 |
| T72038 | DI0190 | Hypertension | [ICD-11: BA00-BA04] | P17931 | LGALS3 |
| T72038 | DI0199 | Idiopathic interstitial pneumonitis | [ICD-11: CB03] | P17931 | LGALS3 |
| T72038 | DI0252 | Melanoma | [ICD-11: 2C30] | P17931 | LGALS3 |
| T72038 | DI0302 | Non-alcoholic fatty liver disease | [ICD-11: DB92] | P17931 | LGALS3 |
| T72038 | DI0351 | Psoriasis | [ICD-11: EA90] | P17931 | LGALS3 |
| T86918 | DI0110 | Cystic fibrosis | [ICD-11: CA25] | P04746 | AMY2A |
| T86918 | DI0328 | Pancreatic malfunction | [ICD-11: DC30-DC3Z] | P04746 | AMY2A |
| T97035 | DI0007 | Acquired hypermelanosis | [ICD-11: ED60] | P14679 | TYR |
| T97035 | DI0008 | Acquired hypomelanotic disorder | [ICD-11: ED63] | P14679 | TYR |